多学科儿童机器人手术项目的前瞻性观察研究:不良事件与发病率
该前瞻性观察研究纳入2016年10月至2020年5月接受机器人辅助腹腔镜手术(RALS)的300例连续患儿,随访至少1年。结果显示65例(22%)出现至少1种并发症,Clavien-Dindo≥III级在≤30天为14/300(5%),30-90天为7/300(2%),>90天为12/300(4%);围术期输血15例(5%),机器人故障8例(3%),总中转率4%。结论认为RALS在儿童中安全,即使在高危患儿中也是如此。
要点
- 儿童RALS总体并发症率22%,严重并发症(Clavien-Dindo≥III)各时间段均较低。
- ASA≥3、体重≤15 kg及肿瘤手术未显著增加中转率、并发症或术中不良事件。
- 机器人故障率3%,总中转率4%,机器人相关并发症少见。
核心结论
- RALS在儿童中安全,即使在高危患儿中也是如此。
- 机器人相关并发症或故障少见。
研究设计与样本
- 前瞻性观察研究,纳入2016年10月至2020年5月接受RALS的300例连续患儿,随访至少1年。
- 使用Da Vinci Xi系统,分析患者特征、手术指征/术式、术中不良事件(ClassIntra分类)、输血、住院时间及术后并发症(Clavien-Dindo)。
主要发现
- 65例(22%)患儿出现至少1种并发症。
- Clavien-Dindo≥III级并发症在≤30天为14/300(5%),30-90天为7/300(2%),>90天为12/300(4%)。
- 围术期输血15例(5%),其中肿瘤患儿8例。
- 机器人故障8例(3%),1例导致中转开腹,总中转率4%。
- 有并发症(Clavien-Dindo≥III)的患儿ASA评分显著高于无并发症者(p=0.01)。
关键数值与推荐
- 并发症分级采用Clavien-Dindo系统,术中不良事件采用ClassIntra分类。
- ASA≥3、体重≤15 kg及肿瘤手术未显著增加中转率、并发症或术中不良事件(ClassIntra≥2)。
临床怎么用
- 儿童RALS可应用于广泛指征、年龄和体重范围,包括高危患儿。
- 需关注ASA评分较高的患儿,其严重并发症风险可能更高。
局限性
- 单中心研究,样本量300例,随访时间至少1年。
- 未报告机器人手术与开放或腹腔镜手术的对照比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report one-year morbidity of robotic-assisted laparoscopic surgery (RALS) in a dedicated, multidisciplinary, pediatric robotic surgery program. Summary Background Data. RALS in pediatric surgery is expanding, but data on morbidity in children is limited. METHODS: All children who underwent RALS (Da Vinci Xi, Intuitive Surgical, USA) were prospectively included (October 2016 to May 2020; follow-up ≥1 year). Analyzed data: patient characteristics, surgical indication/procedure, intraoperative adverse events (ClassIntra classification), blood transfusion, hospital stay, postoperative complications (Clavien-Dindo). RESULTS: Three hundred consecutive surgeries were included: urology/gynecology (n=105), digestive surgery (n=83), oncology (n=66), ENT surgery (n=28), thoracic surgery (n=18). Median age and weight at surgery were 9.5 [interquartile range (IQR)=8.8] years and 31 [IQR=29.3] kg, respectively. Over one year, 65 (22%) children presented with ≥1 complication, with Clavien-Dindo ≥III in 14/300 (5%) children at ≤30 days, 7/300 (2%) at 30-90 days, and 12/300 (4%) at >90 days. Perioperative transfusion was necessary in 15 (5%) children, mostly oncological (n=8). Eight (3%) robotic malfunctions were noted, one leading to conversion (laparotomy). Overall conversion rate was 4%. ASA ≥3, weight ≤15 kg, and surgical oncology did not significantly increase the conversion rate, complications, or intraoperative adverse events (ClassIntra ≥2). ASA score was significantly higher in children with complications (Clavien-Dindo ≥III) than without (p=0.01). Median hospital stay was 2 [IQR=3] days. Three children died after a median follow-up of 20 [IQR=16] months. CONCLUSIONS: RALS is safe, even in the most vulnerable children with a wide scope of indications, age, and weight. Robot-specific complications or malfunctions are scarce.
引用
- Vinit N, Vatta F, Broch A, et al. Adverse Events and Morbidity in a Multidisciplinary Pediatric Robotic Surgery Program. A prospective, Observational Study. Ann Surg. 2023. PMID: 36692109. doi:10.1097/SLA.0000000000005808
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。